STUDIO-PUISTO
15.12.2022 11:44:40 CET | Business Wire | Press release
Solea’s concept of holistic healing answers to the demand of future travellers who look for deeper wellbeing beyond relaxation and meaningful experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005489/en/
Solea Valley Healing resort in Cyprus offers travellers a holistic healing experience surrounded by nature. Image: Studio Puisto
“The increasingly hectic world makes people want to reconnect with nature and take care of their minds and bodies. Wellbeing elements are weaved throughout the entire stay at Solea. We offer our guests more than a vacation, an overall healing experience that will change their life”, says Sam-Erik Ruttmann, Studio Puisto’s Director of Global Hospitality Development.
The site is currently a beekeeping and honey farm and both continue to be an integral part of the location. Guests can study honey production and beekeeping or try apitherapy. Besides the healing spa, the resort has a restaurant, floating pools, sauna and extensive outdoor facilities.
The goal is to minimize impacts to the environment by integrating the resort with the surrounding nature.
"Nature is our inspiration and we want to set an example of how to incorporate it in the design. Beyond preserving, we aim to restore and enhance the diversity of the flora and fauna on site”, says Studio Puisto’s founding partner Willem van Bolderen.
The award-winning Finnish architecture office Studio Puisto specializes in hospitality design. Solea consists of 30 hotel rooms, 40 experiential lodges and 18 exclusive villas with a total capacity of 230 guests. Accommodation prototypes will be completed in early 2023 and the resort is expected to open in 2024.
Responsible travel is conscious travel
Sustainability is considered from materials, construction methods, drainage, lighting and energy solutions to the placement of the buildings.
“Our core value is to design sustainable projects that respect people and the environment. We believe that sustainability should cover the whole design process and the life cycle of the resort”, Van Bolderen continues.
Increasingly, conscious travellers decide their destination, accommodation and activities based on sustainability.
"People want authentic experiences they can enjoy without harming the environment. At Solea, guests can explore nature for example by studying permaculture or by planting a tree. We believe that holistic wellbeing comes from the opportunity to not only focus on oneself, but also to contribute to the wellbeing of the surrounding nature and community”, Ruttmann explains.
Studio Puisto is an architecture and interior design practice specializing in hospitality. The office’s projects are rooted in a Nordic mindset and range globally from a mountain resort in South Korea to a healing resort in Cyprus. Studio Puisto uses architecture as a vehicle to create new experiences and moments with a steadfast commitment of doing it sustainably.
Link
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom